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Abstract: The therapeutic targeting of the programmed death-1 (PD-1)/programmed death 
ligand-1 (PD-L1) axis marked a milestone in the treatment of non-small cell lung cancer 
(NSCLC), leading to unprecedented response duration and long-term survival for a relevant 
subgroup of patients affected by non-oncogene-addicted, metastatic disease. However, the 
biological heterogeneity as well as the occurrence of innate/acquired resistance are well- 
known phenomena which significantly affect the therapeutic response to immunotherapy. To 
date, we are moving towards the second phase of the “immune-revolution”, characterized by 
the advent of new immune-checkpoint inhibitors combinations, aiming to target the main 
resistance pathways and ultimately increase the number of NSCLC patients who may derive 
long-term clinical benefit from immunotherapy. In this review, we provide an updated and 
comprehensive overview of the main PD-1/PD-L1 inhibitors’ combination approaches under 
clinical investigation in non-oncogene addicted, metastatic NSCLC patients, including 
checkpoints (other than CTLA-4) as well as “immune-metabolism” modulators, DNA repair 
pathway inhibitors, antiangiogenic agents, cytokines, and a new generation of vaccines, with 
the final aim of identifying the most promising options on the horizon. 
Keywords: immune-checkpoint, PD-1/PD-L1, resistance, combinations, non-small cell lung 
cancer
Introduction
The application of immune-checkpoint inhibition paradigm to medical oncology is 
anticipated to improve all areas of cancer treatment, including the clinical manage-
ment of lung cancer patients.
Since the introduction of programmed death-1 (PD-1)/programmed death 
ligand-1 (PD-L1) inhibitors in the treatment algorithm of metastatic non-small 
cell lung cancer (NSCLC), we have witnessed a progressive increase of long- 
term survival and quality of life for a relevant subgroup of patients, with about 
30% of them now alive at 5 years, when receiving upfront pembrolizumab for high 
PD-L1 expressing tumors, as compared to 5.5% in the chemotherapy era.1
Alongside single-agent immune-checkpoint inhibitors (ICIs), different randomized 
Phase III studies consistently demonstrated as the addition of immunotherapy to 
upfront chemotherapy synergistically enhance the anti-tumor immune-response and 
prolong patients’ survival, regardless of tumor histotype and PD-L1 expression 
levels,2,3 thus becoming a new standard of care worldwide and ultimately extending 
the percentage of patients who may derive clinical benefit from ICI-therapies. Another 
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investigated strategy included the development of “chemo- 
free” regimens, based on the combination of different ICIs 
with potential complementary effects, such as the PD1 and 
CTLA-4 inhibitors. Two main randomized phase III clinical 
trials compared a dual checkpoint blockade versus first-line 
platinum chemotherapy in patients with epidermal growth 
factor receptor (EGFR) and anaplastic lymphoma kinase 
(ALK) wild-type advanced NSCLC, showing controversial 
results in terms of efficacy. Indeed, the checkmate-227 study4 
demonstrated a significant increase in patients’ overall survi-
val (OS) in favour of the nivolumab plus ipilimumab combi-
nation, regardless of tumor PD-L1 expression as well as 
mutation burden (TMB) levels, leading to the Food and 
Drug Administration (FDA) approval of such combination 
for the treatment of naïve advanced NSCLC patients with 
tumor PD-L1 >1%. Conversely, no survival advantages have 
been reported for the association of durvalumab and treme-
limumab within the different PD-L1 expression subgroups 
analyzed in the MYSTIC trial,5 while the final results of the 
randomized NEPTUNE study (NCT02542293) are still 
pending. More recently a dual PD-1/CTLA-4 blockade com-
bined with a short course (two cycles) of platinum- 
chemotherapy revealed to be more effective and equally 
tolerated than chemotherapy alone, increasing tumor 
response and OS of non-oncogene addicted, metastatic 
NSCLC patients included within the checkmate-9LA 
study,6 emerging as an additional potential upfront option 
for clinical use.
In this exciting scenario, characterized by the contin-
uous advent of innovative drugs and treatment combina-
tions, the occurrence of innate/acquired resistance to 
immunotherapy is a well-known phenomenon which sig-
nificantly affect ICIs’ response at individual patients’ 
level.7 Therefore, developing new ICIs-based combination 
strategies targeting the main resistance pathways and iden-
tifying baseline predictive biomarkers for ICI response, 
beyond PD-L1, represent the areas of intense current 
investigation.
In this review, we provide an updated and comprehen-
sive overview of the main ICIs-based combination 
approaches under clinical investigation in non-oncogene 
addicted, metastatic NSCLC patients, including check-
points (other than CTLA-4) as well as “immune- 
metabolism” modulators, DNA repair pathway inhibitors, 
antiangiogenic agents, cytokines, and a new generation of 
vaccines, with the final aim of identifying the most pro-
mising treatment options on the horizon.
Combinations with Antiangiogenic 
Agents
It is well known that neoangiogenesis and immune-escape 
are interconnected processes. The irregular blood vessels 
enable immune evasion and decrease anti-cancer thera-
pies’ efficacy by limiting the transportation of molecules, 
oxygen, and cytotoxic T cells from the bloodstream to the 
tumor environment. As consequence, the resulting hypoxia 
induces the upregulation of immune checkpoints as well as 
the infiltration of immunosuppressive components, such as 
regulatory T cells (Tregs) and myeloid-derived suppressor 
cells (MDSC), within the tumor microenvironment 
(TME).8 Besides stimulating angiogenesis, vascular 
endothelial growth factor (VEGF) signaling acts itself as 
an immunosuppressive cytokine and its expression has 
been related to immunotherapy resistance. Indeed, VEGF 
signaling inhibits the binding of lymphocytes to endothe-
lial cells and prevents T cell mobilization and tumor infil-
tration by upregulating Fas ligand. Furthermore, it 
promotes Tregs induction and proliferation and suppresses 
the development of dendritic cells.9
In this context, the use of antiangiogenic agents repre-
sents a valuable strategy to adjust tumor vascularization, 
expand immune cells’ infiltration, reduce hypoxia as well 
as the recruitment of immune-suppressive cells, thus ulti-
mately turning into an immune-responsive TME.10
In preclinical NSCLC models, anti-PD-L1 in associa-
tion with vascular endothelial growth factor receptor 
(VEGFR)2 inhibitors significantly reduces PD-L1 expres-
sion, increases tumor-infiltrating lymphocyte (TILs) and 
decreases Tregs and MDSC, thus showing synergistic and 
complementary immune-vascular interactions11 and ulti-
mately supporting the combination of antiangiogenic 
agents and immunotherapy in the clinical setting. 
Different studies investigating the combinations of ICIs 
and antiangiogenics (both monoclonal antibodies targeting 
VEGF, such as bevacizumab, VEGFR, such as ramuciru-
mab, and small molecule tyrosine kinase inhibitors, TKIs) 
have been conducted, others are currently ongoing 
(Table 1), and available preliminary data look promising.
The phase III randomized IMpower-150 trial first 
demonstrated as the upfront combination of 
Atezolizumab, chemotherapy and bevacizumab signifi-
cantly improved OS compared to bevacizumab plus che-
motherapy alone in patients with non-squamous advanced 
NSCLC (hazard ratio (HR): 0.78; 95% CI, 0.64 to 0.96).12 
Importantly, this benefit was demonstrated despite PD-L1 
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expression, with tolerability profile consistent to the pre-
viously reported safety risks of the individual drugs, get-
ting the regulatory approval for clinical use.
The efficacy of the combination of atezolizumab plus 
bevacizumab as first-line chemo-free regimen has been 
also demonstrated by the WJOG@Be study, including 
patients with non-squamous NSCLC and PD-L1 expres-
sion ≥50%. The positive results of this trial have been 
presented recently at the European Society of Medical 
Oncology (ESMO) 2020 meeting, showing 
a considerable ORR of 64.1% with a median duration of 
response of 10.4 months.13 A Phase II randomized trial 
comparing atezolizumab versus atezolizumab plus bevaci-
zumab as first-line treatment in PD-L1-positive advanced 
NSCLC (BEAT trial) is currently ongoing.
The JVDJ trial is a Phase 1a/b single-arm, non- 
randomized, multi-cohort study of ramucirumab plus durva-
lumab in previously treated patients with NSCLC, gastric/ 
gastro-esophageal junction adenocarcinoma (gastric/GEJ), 
or hepatocellular carcinoma (HCC). ORR was 11%, median 
PFS 2.7 months and OS 11.0 months in the NSCLC cohort. 
Patients with PD-L1–high tumours (TPS ≥ 25%) had longer 
median PFS (4.1 versus 2.6 months) and median OS (16.4 
versus 7.5) than the patients in the PD-L1–low subgroup 
(TPS < 25%).14
Similarly, the JVDF trial, is a multicohort, non- 
randomized, phase 1a/b study, enrolling previously treated 
patients with gastric/GEJ adenocarcinoma, NSCLC or 
urothelial carcinoma. The combination of ramucirumab 
and the anti–PD-1 pembrolizumab in the NSCLC cohort 
exhibited durable activity, with higher responses in PD-L1 
positive versus PD-L1–negative patients (unselected: PFS 
9.7, OS 26.2 months; PD-L1–TPS ≥ 1%: PFS 6.9, OS 26.7 
months; PD-L1 TPS < 1%: PFS 9.7, OS 17 months)15. 
Overall the preliminary data emerging from both studies 
are promising and revealed an impressing activity along 
with a manageable safety profile for the association of 
ramucirumab and pembrolizumab in NSCLC patients, 
which need to be confirmed within randomized clinical 
studies.
Recently, the number of studies exploring antiangio-
genics plus ICIs combination has progressively increased 
if we consider also the wide spectrum of multi-target TKIs 
with antiangiogenic properties tested in the clinical setting 
Table 1 Main Ongoing Clinical Trials of Antiangiogenics Agents Combined with ICIs





NCT03377023 NSCLC ≥1 Nintedanib Nivolumab + Ipilimumab I/II
NCT03896074 
(BEAT)
NSCLC 1 Bevacizumab Atezolizumab Compared to: Atezolizumab II
NCT03689855 
(RamAtezo-1)
NSCLC ≥2 Ramucirumab Atezolizumab II





1 Bevacizumab Atezolizumab + chemotherapy II
NCT03527108 NSCLC ≥2 Ramucirumab Nivolumab II
NCT02954991 NSCLC ≥2 Sitravatinib Nivolumab II
NCT03976375 
(LEAP-008)







1 Lenvatinib Pembrolizumab + chemotherapy Compared to: 




NSCLC 1 Bevacizumab Atezolizumab + chemotherapy Compared to: 
Atezolizumab + chemotherapy
III
Abbreviation: NSCLC, non-small cell lung cancer.
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(Table 1). During the 2019 World Conference on Lung 
Cancer (WCLC) Han et al presented the results of a multi- 
cohort phase Ib trial, testing the association of sintilimab 
(anti-PD-1 monoclonal antibody) with anlotinib (multi- 
target TKI) in a treatment-naïve cohort of patients with 
advanced NSCLC. The combination demonstrated 
encouraging anti-tumor activity regardless of PD-L1 
expression, with an ORR of 72.7%, a disease control rate 
(DCR) of 100%, and a 6-month PFS rate of 93.8%. 
Interestingly, in the patient subgroups with high and low 
TMB, the ORR was 85.7% and 63.6%, respectively,16 
while CCL2 (chemokine ligand 2) serological levels 
seem to correlate with anlotinib efficacy.17
In a phase Ib/II trial, the multitarget agent lenvatinib in 
combination with pembrolizumab showed considerable anti-
tumor activity in the cohort of patients with advanced NSCLC, 
leading to a 24 weeks ORR of 33%, a median duration of 
response of 10.9 months and a median PFS of 5.9 months.18
The LEAP-006 is a two-part, phase III study evaluating 
upfront lenvatinib plus pembrolizumab plus platinum-based 
chemotherapy in patients with metastatic non-squamous 
NSCLC. The results of part 1 have been presented at the 
ESMO 2020 meeting, showing acceptable tolerability and 
preliminary evidence of antitumor activity: 13 patients were 
enrolled receiving a median of 10 cycles of combination 
therapy obtaining an ORR of 69.2%. Enrollment in part 2 
is ongoing.19 Lenvatinib is being also tested in combination 
with pembrolizumab versus docetaxel within a phase III 
randomized trial (LEAP-008), including patients with meta-
static NSCLC who failed prior immunotherapy and plati-
num-doublet chemotherapy, in order to evaluate the ability 
of this TKI to restore ICI sensitivity in this cohort of patients. 
Unfortunately, predictive biomarkers to select the best can-
didate to antiangiogenic and immunotherapy combination in 
the clinical setting represent still an unmet need.
Combinations with Other 
Checkpoint Inhibitors
The combination of anti-PD-1 agents with other ICIs is 
based on the assumption that non-responsive tumors use 
immunosuppressive pathways different than PD-1-PD-L1 
axis, including both co-inhibitory and co-stimulatory 
receptors, according to their selective target.
LAG-3
Lymphocyte-activation Gene-3 (LAG-3 or CD223) is a 498 
amino acid type I transmembrane protein binding MHC 
class II molecules.20,21 Alternative ligands, such as 
Galectin-3, LESCtin, alfa-synuclein fibers, were proposed 
to explain some LAG-3 suppressive effects in absence of 
MHC class II. Moreover, a recent work identified FGL-1 as 
a novel, high-affinity and cell-free, LAG-3 ligand, involved 
in the tumor immune evasion processes.22 Although both 
tissue distribution and functional roles of LAG-3 in human 
malignancies have been investigated within several 
studies,21 they have not been clearly defined yet. High PD- 
1 e LAG-3 expression by cytotoxic T CD8+ and NKT cells23 
is consistent with the regulatory action expected from such 
molecules within effector cells. Both targets are also highly 
expressed by Tregs,23 suggesting that may have additional, 
cell-specific suppressive functions, and play a potential role 
in the development of immune tolerance. Of note, both PD-1 
and LAG-3 are preferentially expressed on activated TILs, 
even though such molecules are considered exhaustion 
markers,24,25 confirming that coinhibitory receptors become 
upregulated upon T-cell stimulation in order to limit exag-
gerated responses and potential tissue damage.
The clinical interest towards these molecules resides in 
the negative association between the over-expression of 
LAG-3 and the survival of anti-PD-1-treated NSCLC 
patients. Furthermore, LAG-3 was found to be upregulated 
in NSCLC patients developing acquired resistance to PD-1 
inhibitors. These data apparently suggest that tumors char-
acterized by LAG-3-mediated immune-escape, are less 
sensitive to PD-1 inhibition, thus paving the way to the 
association of PD-1 and LAG3 ICIs as therapeutic strategy 
for non-oncogene addicted advanced NSCLC.
Recent results from a dose escalation phase I/II study 
of LAG525 ± Spartalizumab in metastatic malignancies 
(NCT02460224) showed that this combination was well 
tolerated with preliminary anti-tumor activity and 
immune profile modulation observed in the included 
population.26 Phase II studies are currently exploring 
the efficacy and safety profiles of either Eftilagimod 
alpha plus Pembrolizumab (NCT03625323) or BMS- 
986,016 plus Nivolumab (NCT01968109) combinations 
in both treatment naïve and ICI-resistant metastatic 
NSCLC patients and the results will provide us relevant 
information about the perspectives of LAG-3 targeting 
in NSCLC.27
Several trials are currently being conducted with the 
aim of evaluating the role of anti-LAG-3 agents in 
patients with advanced solid tumors, including NSCLC 
(Table 2).
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TIM-3
T-cell immunoglobulin and mucin domain 3 (Tim-3) is an 
immunoglobulin (Ig) containing cell surface molecule which 
is expressed among distinct immune-cells populations, 
including CD4+, CD8+28 T regulatory,29 Th17 cells,30 den-
dritic cells, B cells, macrophages, NK and mast cells. 
Differently from other checkpoints receptors, as PD-1 and 
TIGIT, Tim-3 lacks classical immunoreceptor tyrosine-based 
switch signaling motifs in its cytoplasmatic tail. So far, four 
distinct ligands for Tim-3 have been identified: galectin-9, 
phosphatidylserine (PtdSer), high-mobility group protein B1 
(HMGB1) and CECAM-1. Tim-3 is certainly co-regulated 
and co-expressed alongside other immune checkpoint recep-
tors (PD-1, LAG-3 and TIGIT) on both CD4+ and CD8+ 
T cells,31,32 specifically marking the most dysfunctional and 
terminally exhausted subset of CD8+ T cells.33,34
Moreover, Tim-3 has been detected on both TILs and 
NSCLC cells, and its high levels have been related to poor 
patients’ prognosis,35 particularly when it was expressed by 
CD4+ cells.29 Pre-clinical evidence showed that Tim-3 
overexpression is associated with PD-1 inhibitor resistance, 
suggesting that selective Tim-3 blockers may likely repre-
sent a valid therapeutic option at the time of anti-PD-1 
treatment failure.36 Specifically, concomitant inhibition of 
PD-1 and Tim-3 looks promising,34 with several ongoing 
clinical trials investigating anti-Tim-3 in combination with 
anti-PD-1 inhibitors in advanced solid tumors (Table 3). 
A Phase II dose-expansion trial (NCT02608268), exploring 
the combination of MBG453 and spartalizumab, showed 
good tolerance but limited efficacy in patients with mela-
noma and NSCLC who failed prior anti-PD-1/PD-L1 ther-
apy. In this trial 33 patients (melanoma: n=16; NSCLC: 
n=17) received MBG453 (800 mg, Q4W) plus spartalizu-
mab (400 mg, Q4W) until unacceptable toxicity, progression 
disease (PD), or investigator’s/patients’ decision. On prior 
anti–PD-1/PD-L1 therapy, 6 (37.5%) melanoma and 7 
(41.2%) NSCLC patients experienced durable clinical ben-
efit, defined as complete, partial response, or stable disease 
(SD) for more than 6 months since treatment initiation. 
Common treatment-related adverse events (TRAEs) were 
reported in about 9% of the cases, while only 11.8% of 
NSCLC patients experienced grade 3–4 TRAEs.37 Further 
evaluation of MBG453 in other indications/combinations is 
warranted to assess the clinical relevance of Tim-3 inhibi-
tion in the clinical setting.
Other clinical trials are currently being conducted with 
the aim of evaluating the role of anti-Tim-3 drugs in patients 
with advanced solid tumors, including NSCLC (Table 3).
TIGIT
T cell immunoglobulin and ITIM domain (TIGIT) is a T cell 
and natural killer (NK) inhibitor receptor38 critical to the 
immune tolerance development. It seems to preserve suppres-
sor functions of Treg cells,39 while TIGIT-positive NK cells 
have been associated with tumor progression.40 In pre-clinical 
Table 2 Main Ongoing Clinical Trials of Anti-LAG-3 Agents Combined with ICIs
Clinical Trial Cancer Type Treatment 
Line
Anti-LAG3 Agent Immunotherapy Phase
NCT03625323 NSCLC ≥1 Eftilagimod alfa Pembrolizumab II
NCT01968109 Advanced solid 
tumors
≥2 BMS-986,016 Nivolumab Ib/II
NCT02460224 Advanced 
Malignancies
≥2 LAG525 PDR001 (anti-PD-1 mAb) I/II
NCT03684785 Advanced solid 
tumors
≥2 Cavrotolimod Pembrolizumab or 
cemiplimab
Ib/II
NCT03156114 Advanced solid 
tumors
≥2 BI 754,111 BI754091 (anti-PD-1 mAb) I
NCT04140500 Advanced solid 
tumors
≥2 RO7247669 (anti-PD-1-LAG-3 Bispecific 
mAb)
- I
NCT03849469 Advanced solid 
tumors
≥2 XmAb®22,841 Pembrolizumab I
Abbreviations: NSCLC, non-small cell lung cancer; mAb, monoclonal antibody.
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models of both cancer and chronic viral infection, antibody 
co-blockade of TIGIT and PD-L1 synergistically enhanced 
CD8+ T cell effector function, resulting in significant tumor 
and viral clearance responses,41 which makes TIGIT a new 
interesting therapeutic target for the clinical setting.
According to phase II data coming from the 
CITYSCAPE study, presented at the American Society for 
Clinical Oncology (ASCO) 2020 Meeting, the addition of 
the anti-TIGIT antibody Tiragolumab to the anti-PD-L1 
atezolizumab resulted in a clinically meaningful improve-
ment of both ORR and PFS, in patients with treatment 
naïve, PD-L1 high, non-oncogene addicted advanced 
NSCLC. In this prospective, randomized, placebo- 
controlled trial, 135 patients with tumor PD-L1 ≥ 1%, 
were randomized 1:1 to receive Tiragolumab plus atezoli-
zumab (n=67) or placebo plus atezolizumab (n=68). At 
a median follow-up of 10.9 months, a significant improve-
ment in ORR (37.3% versus 20.6%) and PFS (5.6 versus 
3.9 months) was observed in favour of the experimental 
arm. Interestingly, when patients were analyzed according 
to their tumor PD-L1 expression levels, the clinical benefit 
was limited to those with TPS � 50%, with ORR of 66% 
for Tiragolumab plus atezolizumab compared to 24% for 
the placebo arm. All grade TRAEs occurred in 80.6% 
versus 72% of cases, with grade � 14.9% and 19.1%, 
respectively.42 These data overall suggested that 
Atezolizumab plus Tiragolumab combination may represent 
an attractive option for the treatment of PD-L1 high 
NSCLC patients, with clinical efficacy to be confirmed 
within ongoing randomized phase III clinical studies 
(SKYSCRAPER-01, SKYSCRAPER-03) (Table 4).
OX-40
OX-40 is a type1 transmembrane receptor, member of the 
tumor necrosis factor receptor (TNFR) family, expressed by 
activated CD4+ and CD8+ T cells during the antigen-specific 
priming.43–45 The activation of OX-40/OX-40L axis works 
as a co-stimulatory signal for CD4+ and CD8+ T cells 
activation, clonal division, cytokine production and estab-
lishment of T cells memory.46 In particular, OX-40 pathway 
promotes the transformation of CD4-positive T cells into 
T helper cells, by enhancing interleukin and interferon 
secretion,47–50 with preclinical data indicating its crucial 
role in the long-term survival of CD4+ and CD8+ T cells.51
He et al recently found that low levels of OX40 expres-
sion on TILs correlated with longer OS and recurrence- 
free survival (RFS) of NSCLC patients who underwent 
early-stage tumor resection. In their case series OX40 
expression correlated with PD-L1 expression on tumor 
cells.52 Kashima et al observed that high OX40 and 
OX40L levels were associated with poor prognosis and 
may reflect the immune-exhausted status against lung 
adenocarcinoma.53 Moreover, Massarelli et al found that 
high OX40 expression within tumor immune infiltrate was 
associated to favorable prognosis in surgically resected 
stage I–III NSCLC patients, suggesting a potential role 
for the selection of candidate to OX40 agonist 
antibodies.54
Table 3 Main Ongoing Clinical Trials of Anti-Tim-3 Agents Combined with ICIs
Clinical Trial Cancer Type Treatment 
Line
Anti-Tim-3 Agent Immunotherapy Phase
NCT03099109 Advanced solid tumors ≥2 LY3321367 LY3300054 (anti-PD-L1 
mAb)
I
NCT03307785 Advanced solid tumors ≥2 TSR-022 TSR-042 (anti-PD-L1 
mAb)
I
NCT03311412 Advanced solid tumors 
and/or lymphomas
≥2 Sym023 Sym021 (anti-PD-1 
mAb)
I
NCT02817633 (AMBER) Part 1 
Part2 cohort B (NSCLC)
Advanced solid tumors ≥2 TSR-022 Nivolumab or TSR-042 
(anti-PD-1 mAb)
I
NCT03708328 Advanced solid tumors ≥2 RO7121661 (anti-PD-1/ 
TIM-3 bispecific mAb)
– I
NCT03744468 Advanced solid tumors ≥2 BGB-A425 Tislelizumab (anti-PD-1 
mAb)
I/II
Abbreviations: NSCLC, non-small cell lung cancer; mAb, monoclonal antibody.
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Due to its biological functions and according to the existing 
evidences, the OX40-OX40L axis is expected to be a potential 
target of immunotherapy-based strategies for solid 
tumors.52,55–57
At the ASCO 2020 meeting Goldman et al showed 
encouraging Phase I trial results of MEDI0562, a humanized 
IgG1k OX40 monoclonal antibody (mAb) in combination with 
durvalumab (anti-PD-L1 mAb) or tremelimumab (anti-CTLA 
-4 mAb) in patients with previously treated advanced solid 
tumors (NCT02705482). Median OS was 17.4 and 11.9 
months for MEDI0562 plus durvalumab and tremelimumab, 
respectively, with SD seen in 9 patients from each group 
(34.6% versus 29.0%, respectively). The safety profile of 
MEDI0562 in combination with durvalumab or tremelimumab 
was similar between groups.58
In a phase I trial of advanced solid tumors, Infante et al 
showed a tolerable profile for vonlerolizumab plus 
atezolizumab combination, with evidence of PD-L1 induction 
and immune activation in tumor-paired biopsies 
(NCT02410512).59 In the same target population, another 
ongoing phase 1 trial of GSK3174998 administered as mono-
therapy or combined with pembrolizumab (anti-PD-1 Ab) 
showed no dose-limiting toxicities (NCT02528357).60
Table 5 shows currently ongoing phase I/II trials test-





Nowadays, it is emerging that immune response may be 
influenced by different metabolic pathways, involving 
both tumor and effector CD8+ cells, which partially 
Table 5 Main Ongoing Clinical Trials of OX40 Agonistic Agents Combined with ICIs
Clinical Trial Cancer Type Treatment 
Line
OX40 Agonistic mAb Immunotherapy Phase
NCT02528357 Advanced solid 
tumors
≥2 GSK3174998 Pembrolizumab I
NCT02410512 Advanced solid 
tumors
≥2 MOXR0916 Atezolizumab Ib
NCT02554812 Advanced solid 
tumors
≥2 PF-04518600 (OX40 agonist mAb) Avelumab Ib/II
NCT02221960 Advanced solid 
tumors





≥2 INCAGN01949 Nivolumab or 
ipilimumab
I/II
Abbreviations: NSCLC, non-small cell lung cancer; mAb, monoclonal antibody.
Table 4 Main Ongoing Clinical Trials of Anti-TIGIT Agents Combined with ICIs
Clinical Trial Cancer Type Treatment Line Anti-TIGIT 
Agent
Immunotherapy Phase
NCT03119428 Advanced solid 
tumors
≥2 OMP-313M32 Nivolumab I
NCT03628677 Advanced solid 
tumors
≥2 AB154 AB122 (anti-PD-1 mAb) Zimberelimab I
NCT04294810 
SKYSCRAPER-01





NSCLC (Stage III) Consolidation after 
CRT
Tiragolumab Atezolizumab Compared to: Durvalumab III
Abbreviations: NSCLC, non-small cell lung cancer; mAb, monoclonal antibody; CRT, chemoradiation.
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compete for the same resources within the tumor TME.61 
Hence, new combination strategies which are able to 
manipulate the immunosuppressive TME and to enhance 
antitumor T cell responses are under investigation.
Preclinical studies identified multiple immunosup-
pressive mechanisms in the T-cell-inflamed tumors, 
including metabolic mechanisms of immunosuppression, 
such as the tryptophan-kynurenine-aryl hydrocarbon 
receptor (Trp-Kyn-AhR) pathway, which is the primary 
route for tryptophan catabolism.62,63 Kynurenine acts as 
a powerful AhR agonist, a ligand-gated transcription fac-
tor expressed by immune cells, which regulates a wide 
range of immunomodulatory effects.64,65 In preclinical 
models, heightened activities of the Trp-Kyn-AhR path-
way have been related to the impairment of antitumor 
immunity and tumor growth.66,67 Three enzymes catalyze 
tryptophan conversion into kynurenine: IDO1, IDO2 and 
TDO.68 In murine cancer models, high IDO levels were 
associated with a reduced T lymphocytes infiltration. 
Elevated IDO1 and TDO activity as well as Kyn levels 
were associated to an increased tumor grade as well as 
a poor prognosis in different tumor types.69 Preclinical 
series showed that 40% of NSCLC express IDO1 with no 
significant differences between squamous and non- 
squamous subtype. Finally, IDO-1 overexpression has 
been observed after PD-1/PD-L1 ICIs treatment in 
NSCLC patients, suggesting its potential role in the con-
text of acquired resistance, and has been correlated to 
worse patients’ prognosis.70
Based on these considerations, this pathway represents 
an attractive therapeutic target for cancer treatment, with 
different molecules currently under investigation, but 
phase I/II/III clinical trial results available only for IDO- 
1 inhibitors. Particularly, the anti-IDO-1 epacadostat has 
reached the most advanced stage of clinical development, 
with the recent publication of the ECHO-301/Keynote-252 
phase III trial results showing no survival advantage from 
the addition of epacadostat to pembrolizumab in metastatic 
melanoma.71 These negative results were totally unex-
pected, since early phase trials of this combination in as 
many as 14 different solid tumors had previously shown 
promising activity.72 Significant differences among treat-
ment populations, as well as inappropriately low dosing of 
epacadostat, with subsequent incomplete suppression of 
intratumoral Kyn pathway, may only partially explain the 
observed discrepancy. It is supposed that IDO-1 inhibition 
alone is likely inadequate to lowering intratumoral Kyn 
levels, thus paving the way to new combinations.73–76
Even though the combination of epacadostat and pem-
brolizumab have largely disattended previous expectations 
in melanoma, a phase II clinical trial is currently investi-
gating its potential activity in treatment-naïve NSCLC 
patients characterized by high tumor PD-L1 expression 
(NCT03322540). Furthermore, there is still a great interest 
towards the investigation of Trp-Kyn-AhR pathway inhibi-
tion, with selective IDO-1 inhibitors (BMS-986,205, 
NLG-919 (navoximod/GDC-0919), dual IDO/TDO inhibi-
tors (RG70099 and IOM-D) as well as indoximod plus 
anti-PD-1 combinations, currently in early stages of clin-
ical development (NCT03343613, NCT03322540, 
NCT02298153, NCT03562871).
Cytokines: TGF-ß
Transforming growth factor- ß (TGF-ß) is a pleiotropic 
cytokine with dual role in cancer progression, acting both 
as tumor cells plasticity inducer and antitumor immune 
response suppressor.
TGF-ß trouble immune balance by holding the cyto-
toxic activity of NK cells77 and by favouring Tregs 
differentiation.78,79 On the other hand, TGF-ß acts as 
a key regulator of epithelial-mesenchymal transition 
(EMT) process, thus playing a role to the development of 
drug resistance among different cancer types. Particularly 
recent studies demonstrated the importance of TGF-β as 
a mechanism of resistance to ICI-therapies, leading to the 
clinical development of numerous new drugs targeting the 
TGF-β pathway, including small molecule inhibitors, anti-
bodies and receptor-based TGF-β traps.80
Galunisertib is an oral small molecule inhibitor of 
TGF-β kinase receptor type I (TGF-β RI/ALK5)81 which 
selectively inhibits the serine/threonine activity, thereby 
preventing the phosphorylation of downstream proteins, 
SMAD2 and SMAD381. The antitumor activity of galuni-
sertib has been demonstrated in three different in vivo 
tumor models, including NSCLC.82,83 Results from the 
phase II trial exploring the combination between galuni-
sertib and nivolumab in recurrent or refractory NSCLC 
(NCT 02423343) are not available yet.
Several TGF-β-directed mAbs are currently under clin-
ical evaluation. Among these, fresolimumab (GC1008), 
a fully human anti-TGF-β mAb targeting all TGF-β iso-
forms, has recently completed phase I clinical trial 
(NCT00356460), showing acceptable safety signals in 
renal cell carcinoma, melanoma and glioma84 and is cur-
rently being investigated in phase I/II trials including 
advanced solid tumors and mesothelioma.
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Bintrafusp alfa is an antibody–drug conjugate (ADC) 
designed to simultaneously target both TGF-β and PD-L1 
suppressive pathways that are commonly used by cancer 
cells to evade the immune system.
The dose-escalation portion of a Phase I, open-label 
clinical trial of bintrafusp alfa (MSB0011359C) has been 
completed, showing promising antitumor efficacy in heav-
ily pretreated patients with metastatic solid tumors.85
Most recently, Paz-Ares et al showed encouraging effi-
cacy and manageable tolerability associated with this 
agent within an expansion cohort of a phase I study, 
including 80 pretreated patients with metastatic NSCLC 
receiving bintrafusp alfa 500 or 1200 mg (n=40 each). At 
a median follow-up of 51.9 weeks, the ORR was 17.5% 
and 25% for the 500 mg and the 1200 mg doses, respec-
tively, while reaching about 86% in the subgroup of 
patients with very high tumor PD-L1 expression (TPS �
80%), while TRAEs occurred in about 69% of the 
patients.86 Based on these data, Bintrafusp alfa is currently 
being compared with pembrolizumab as an initial treat-
ment for patients with advanced NSCLC and high tumor 
PD-L1 expression (NCT03631706).
Stimulator of Interferon Genes: STING
STING (Stimulator of Interferon Genes) is a component 
of the endoplasmic reticulum (ER) which is essential for 
the production of type I interferon (IFN) in fibroblast, 
macrophages and dendritic cells (DCs), in response to 
cytoplasmic double-strand DNA ds(DNA) breaks as 
well as selected DNA viruses and intracellular 
bacteria.87,88 Type I IFN functions in a paracrine or auto-
crine manner, enhancing DCs cross-presentation activity 
and T cell activation. Particularly STING works as an 
adaptor protein that enhances the immune signaling fol-
lowing pathogen DNA detection by cytoplasmic DNA 
sensors (DAI, DHX9, DHX36, IFI204 etc)89. The recog-
nition of microbial nucleic acids is one of the major 
mechanisms by which the immune system detects patho-
gens and STING plays a crucial role in the induction of 
immune response following DNA detection. Several stu-
dies identified type I IFN as a critical mediator in the 
spontaneous priming of antitumor CD8+ T cell 
responses.90 Accordingly, Woo and colleagues reported 
that the spontaneous CD8+ T cell priming against tumor 
cells was defective in mice lacking STING expression. 
Moreover, STING-deficient mice were unable to generate 
efficient antitumor T cell responses and prevent mela-
noma growth.
Della Corte et al demonstrated that STING pathway 
activation in NSCLC predicted features of immunotherapy 
response and was enhanced under cisplatin 
chemotherapy.91
On this basis, the combination of STING agonists with 
ICIs is emerging as a promising option, considering that 
STING pathway activation could “heat up” an immunolo-
gically cold tumor and trigger infiltration by immune cells, 
which in turn can be unleashed by the checkpoint block-
ade. Therefore, this kind of combination would allow to 
successfully target specific tumors that are usually refrac-
tory to single-agent immune checkpoint blockade. The 
development of STING agonists has rapidly grown as 
a novel class of immunotherapy, either alone or in combi-
nation with ICIs. STING agonists may be grouped into 
two main subtypes: nucleotidic or non-nucleotidic 
agonists.
Encouraging preclinical results have brought ADU- 
S100 forward to Phase I clinical trials, where it is admi-
nistered by intratumoral injection to patients with 
advanced metastatic solid tumors or lymphomas, alone or 
in combination with ipilimumab (NCT02675439) or with 
anti-PD1 agents (NCT03172936).
Preliminary results of the phase 1 MK-1454, multi-
center, dose escalation study exploring the MK-1454 as 
monotherapy (Arm 1) or in combination with pembrolizu-
mab (Arm 2) in patients with solid tumors showed 
encouraging efficacy and an acceptable safety profile sup-
porting the subsequent development of this combination 
regimen. TRAEs occurred in 83% and 82% of the patients 
in Arms 1 and 2, respectively, with only 9% and 14% of 
grade ≥3, 7% discontinuation in Arm 2 (0% in Arm 1), 
and no TRAEs-related deaths. PR were observed in 6 of 
25 (24%) patients in Arm 2 (0% in Arm 1), while DCR 
was 20% in Arm 1 and 48% in Arm 2. Dose escalation 
trial is currently ongoing (NCT03010176),92 with final 
results expected within the end of 2021. Results from the 
Phase Ib dose escalation study exploring MIW815 (ADU- 
S100) plus spartalizumab in patients with advanced solid 
tumors supported synergistic antitumor effects when 
MIW815 (ADU-S100) was combined with ICIs 
(NCT03172936)93 but no specific data on NSCLC are 
available yet. The 5,6-dimethylxanthenone-4-acetic acid 
(DMXAA), also known as vadimezan or ASA404, is 
now recognized as a non-nucleotidic STING agonist and 
has rapidly entered clinical trials. However, DMXAA is 
a poor agonist of human STING and ultimately failed 
within phase III NSCLC clinical trials in combination 
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with chemotherapy.94 Currently, non-nucleotidic STING 
agonists have not yet reached the clinical trials stage.
Despite all this encouraging evidence showing the 
rationale for implementing STING targeting therapy into 
the clinic, further characterization of the STING pathway 
is necessary for the development of tailored and effective 
combination treatments.
Combinations with PARP Inhibitors
The capacity of cancer to restore DNA damage is a crucial 
determinant of clinical response to ICIs. Indeed, genetic 
unstable and highly mutated cancers are usually characterized 
by increased tumor neoantigens load, thus likely to better 
respond to immunotherapy. Hsiehchen et al demonstrated 
that nucleotide excision repair as well as the homologous 
recombination (HR) gene defects are correlated with longer 
survival in cancer patients receiving ICIs.95 In the context of 
DNA repair pathways, poly (ADP-ribose) polymerase 
inhibitors (PARPi) represent a novel treatment strategy to 
selectively kill a subset of HR-deficient cancer cells by indu-
cing synthetic lethality.96 Recent data suggested that besides 
its direct cytotoxic activity, PARP inhibition can have also 
immunomodulating effects, by increasing TMB, IFN-1 
release, PD-L1 expression, and T-cell infiltration, thus poten-
tially improving clinical response to immunotherapy.97,98 
These data provided the biological rationale for the design 
of clinical trials investigating the combinations of PARPi and 
ICIs therapies in different tumor types, including lung cancer. 
Considering the prevalence of germline and/or somatic 
defects in the HR genes is reported to be around 5% in 
NSCLC,99 several clinical trials are currently assessing the 
efficacy and tolerability of this kind of combinations in dif-
ferent settings (Table 6).
The ongoing phase II ORION trial (NCT03775486) 
was designed to evaluate the efficacy and safety of durva-
lumab plus olaparib versus durvalumab alone as 
Table 6 Main Ongoing Trials of PARPi Combined with ICIs





UNITO–001 HRR-positive and PD-L1 ≥ 1% 
advanced NSCLC and/or MPM
≥2 Niraparib TSR-042 (anti-PD-1 mAb) II
NCT03307785 Advanced or metastatic cancer ≥1 Niraparib TSR-042 (anti-PD-1 mAb) I
NCT02484404 Advanced or metastatic cancer N line Olaparib Durvalumab I/II
NCT03559049 Non-squamous NSCLC Maintenance Rucaparib Pembrolizumab I/II
NCT03308942 NSCLC 1/2 Niraparib Pembrolizumab/TSR-042 (anti-PD-1 mAb) II
NCT03330405 NSCLC, TNBC, HR+ breast cancer, 
ovarian cancer, UC, CRPC.
≥1 Talazoparib Avelumab II
NCT03334617 
(HUDSON)
NSCLC ≥2 Olaparib Durvalumab II
NCT03775486 
(ORION)
NSCLC Maintenance Olaparib Durvalumab Compared to: Durvalumab II
NCT03976323 
(KEYLYNK-006)





Squamous NSCLC Maintenance Olaparib Pembrolizumab Compared to: 




NSCLC Maintenance Olaparib Pembrolizumab Compared to: 







≥2 Talazoparib Avelumab II
Abbreviations: TNBC, triple-negative breast cancer; HR+, hormone receptor-positive; UC, urothelial cancer; CRPC, castration-resistant prostate cancer.
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maintenance therapy in patients affected by stage IV 
NSCLC not progressing after a first-line platinum-based 
chemotherapy plus durvalumab.100 Moreover, two phase 
III trials are evaluating the superiority of pembrolizumab 
plus maintenance olaparib versus maintenance pemetrexed 
in non-squamous NSCLC [KEYLYNK-006, 
NCT03976323] and of pembrolizumab with or without 
maintenance olaparib for squamous NSCLC 
[KEYLYNK-008, NCT03976362].
The HUDSON international, multi-arm, umbrella trial is 
specifically investigating the role of biomarker-directed com-
bination strategies (durvalumab + PARP/STAT3/ATR/ 
mTORC inhibitors) for NSCLC patients progressed on ICIs. 
Particularly patients with HR repair defects and LKB1 aberra-
tion will be treated with durvalumab and olaparib. Similarly, 
the NCT04173507 is a phase II trial investigating the efficacy 
of talazoparib plus avelumab combination in metastatic non- 
squamous NSCLC harboring STK11 gene mutation, while 
UNITO-001, is a Phase II, single-arm study, investigating the 
safety and antitumor activity of the PARPi niraparib plus 
dostarlimab (anti-PD-1 agent) in HRR-positive and PD-L1 
≥1% advanced NSCLC and/or malignant pleural mesothe-
lioma patients. The results of these studies will likely provide 
interesting evidence about the ability of PARPi to restore ICI 
sensitivity in this molecularly selected cohort of patients.101
The interest in PARPi and ICIs combination involves 
also earlier clinical stages: the KEYLYNK-012 trial is 
a Phase 3, placebo-controlled study, in which pembrolizu-
mab with concurrent chemoradiation therapy followed by 
pembrolizumab with or without olaparib will be compared 
to concurrent chemoradiation therapy followed by durva-
lumab in stage III NSCLC patients.102
The results of the aforementioned randomized studies 
are eagerly awaited and will be fundamental to evaluate 
the real benefit of the association of PARPi and immu-
notherapy in NSCLC patients.103
Combinations with Cancer Vaccines
Cancer vaccines represent an attractive treatment option 
for different tumor types, since their ability to sensitize 
host immune system and ultimately induce a specific 
T-cell mediated immune response against tumor 
antigens.104 Vaccination may be based on peptides 
derived from cancer antigens, recombinant cancer anti-
gen proteins, recombinant viral vectors, tumor antigen- 
loaded dendritic cells, or DNA/RNA-encoding tumor 
antigens. Nowadays particular attention is reserved to 
personalized vaccines targeting individually selected 
shared antigens, in different cancer settings.104 
Moreover, vaccines can upregulate PD-L1 expression 
within the TME, favoring the transition of immunologi-
cally cold into hot tumors, thus providing a strong ratio-
nale for the association to ICIs.105 Interestingly, ICIs 
themselves could increase the efficacy of vaccines in 
different ways: CTLA-4 inhibition can boost the ampli-
tude of the priming phase by enhancing T-cell response, 
and can inhibit T-regs in the TME, while anti-PD-1/PD- 
L1 agents promote T-cells activity inside the TME 
increasing the amplitude of vaccine-mediated T cell 
responses.106 Based on several preclinical studies show-
ing the additive and synergistic effects of vaccines and 
ICIs association, different clinical trials are ongoing.
Viagenpumatucel-L (HS-110) is an allogeneic cellular 
vaccine derived from a human lung adenocarcinoma cell 
line. The phase I/II DURGA trial (NCT02439450) is test-
ing its combination with nivolumab in patients with pre-
viously treated advanced NSCLC. Preliminary results in 
the ICI-resistant cohort showed a good tolerability and 
responsiveness with a DCR of 55% and a PFS of 2.7 
months (95% CI, 1.8–4.0 months).102
TG4010 is a cancer vaccine based on a viral vector, 
a Modified Vaccinia Virus Ankara (MVA) that codifies 
for MUC-1 (an antigen found in NSCLC) and for 
interleukin-2.107 Two different phase II studies are 
ongoing, evaluating the association of TG4010 with 
ICIs. One of them is testing the combination of 
TG4010 and nivolumab in previously treated non- 
squamous NSCLC patients (NCT02823990), the other 
one is evaluating the efficacy of first-line TG4010, nivo-
lumab and chemotherapy in patients with PD-L1<50% 
(NCT03353675). DIRECT-01 is an ongoing open-label 
phase I/IIa trial, aiming to explore the safety, immuno-
genicity and efficacy of VB10.NEO, a DNA plasmid 
vaccine with intrinsic adjuvant effect designed for effi-
cient delivery of personalized neoepitopes, in association 
with immunotherapy in patients with locally advanced or 
metastatic solid tumors including NSCLC.108 DSP-7888 
is a therapeutic cancer vaccine composed of two syn-
thetic peptides derived from Wilms’ tumor 1 (WT1) 
that can promote both cytotoxic and helper 
T-lymphocyte-mediated immune responses against WT1- 
expressing tumors. WT1 is overexpressed in various solid 
tumors. A phase Ib/II study is being conducted to evalu-
ate DSP-7888 in combination with nivolumab or pem-
brolizumab in advanced solid tumors, including NSCLC 
patients (NCT03311334). Other several combination trials 
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are ongoing and the results are awaited (Table 7). As for 
ICIs, not all patients respond to vaccines and the detec-
tion of predictive biomarkers represents a crucial point to 
select the best candidate for this treatment strategy. As 
known, lung cancer is often characterized by lack of 
HLA class I expression that is important for peptide 
recognition by lymphocytes. Thus, HLA expression is 
currently under investigation as predictive biomarker in 
clinical studies with cancer vaccines.109 Besides the high 
scientific appealing for these combinations, to date, clin-
ical data are mostly lacking or still immature, at least in 
lung cancer, therefore the use of vaccines, remains 
experimental. Hopefully, progress in immune system 
knowledge and biological technologies will help to 
make vaccines plus ICIs combination, an effective, safety 
and accessible treatment option, tailored on every 
NSCLC patient.
Discussion
The introduction of ICIs targeting the PD-1/PD-L1 axis in 
clinical practice marked a milestone in the treatment of 
NSCLC, leading to unprecedented response duration and long- 
term survival for a relevant subgroup of patients affected by 
non-oncogene-addicted, metastatic disease. To date, we are 
facing the second phase of the “immune-revolution”, which 
is largely dominated by the advent of combination strategies. 
Different chemotherapy-ICIs regimens, have already entered 
in our current practice, allowing to extend the clinical benefits 
of immunotherapy to a larger fraction of NSCLC patients 
whose tumor harbor low or negative PD-L1 expression. As 
regards dual checkpoint blockade treatment, the combination 
of PD-1/PD-L1 plus CTLA-4 inhibitors was investigated 
within randomized trials, leading to regulatory approval of 
nivolumab plus ipilimumab either alone or in combination 
with chemotherapy as first-line treatment in metastatic 
NSCLC patients. However, the high rate of severe immune- 
related toxicities posed a major limitation to the clinical use of 
such combination, whose specific place in our real-word treat-
ment algorithm remains still to be defined. Although the advent 
of the “first round” of ICIs combinations allowed to offer 
upfront immunotherapy to almost all patients with newly diag-
nosed, metastatic, non-oncogene addicted NSCLC, only 
a limited number of them still achieve durable response, with 
innate/acquired resistance occurring in most cases during the 
treatment course. On this basis, the “second round” of combi-
nations (Figure 1) has been specifically designed to target the 
main resistance mechanisms occurring at the different time 
points of the cancer immunity cycles, in order to delay patients’ 
disease progression and ultimately increase the bar of long- 
term survivors under ICI therapies. Among the different com-
binations reaching the most advanced stages of clinical devel-
opment, the upfront association of the anti-TIGIT mAb, 
Tiragolumab, with the anti-PD-L1 agent, atezolizumab, has 
recently emerged as a promising approach to further increase 
Table 7 Main Ongoing Trials of Cancer Vaccines Combined with ICIs
Trial Cancer Type Line of 
Treatment
Vaccine Immunotherapy Phase
NCT03380871 Non-squamous NSCLC 1 NEO-PV-01 Pembrolizumab + chemotherapy I
NCT03647163 NSCLC ≥2 VSV-IFNβ-NIS Pembrolizumab I
NCT04266730 Squamous NSCLC, SCCHN ≥1 PANDA-VAC Pembrolizumab I
NCT03948763 NSCLC, CRC, Pancreatic 
Neoplasms
≥3 V941 Pembrolizumab I
NCT03311334 Solid tumors ≥2 DSP-7888 Nivolumab I/II
NCT02955290 NSCLC, SCCHN ≥2 CIMAvax Nivolumab I/II
NCT02879760 NSCLC ≥3 Ad-MAGEA3 and MG1- 
MAGEA3
Pembrolizumab I/II
NCT02823990 Non-squamous NSCLC ≥2 TG4010 Nivolumab II
NCT03353675 Non-squamous NSCLC 1 TG4010 Nivolumab + Chemotherapy II
Abbreviations: CRC, colorectal cancer; SCCHN, squamous cell carcinoma of the head and neck.
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the survival benefit reached with single-agent PD-1 mAb in the 
subgroup of patients harboring high tumor PD-L1 expression, 
and is currently under evaluation within phase III randomized 
trials. Conversely, the combination of epacadostat and pem-
brolizumab has largely disattended previous expectations, con-
sidering the negative results observed in melanoma patients, 
and the potential role of IDO inhibitors as enhancer of PD-1 
therapy activity in lung cancer remains undefined. The simul-
taneous inhibition of angiogenesis and PD-L1 pathways either 
alone or in combination with chemotherapy has already proven 
to be a valid strategy in non-squamous NSCLC, with the 
VEGF mAb, bevacizumab, approved for clinical use, and the 
VEGFR mAb, ramucirumab, emerging as an additional pro-
mising effective option in this setting. Pre-clinical data pro-
vided a strong rationale for the use of both PARPi and cancer 
vaccines in combination with ICIs, since their ability to 
enhance/restore PD-1 treatment activity against tumor- 
associated antigens. Although clinical evidence coming from 
early phase I studies seem to support this hypothesis, they are 
very preliminary and experimental data. The results of the 
ongoing phase II/III studies will be crucial to establish whether 
these treatments will be able to turn immunologically cold/ 
excluded tumors into hot/inflamed ones and ultimately 
enhance ICIs-response in NSCLC patients. An actual and 
controversial issue related to the upcoming advent of these 
treatment approaches regards their tolerability, since the risk of 
adverse events related to the immunization significantly 
increase with the use of combination strategies, especially 
when considering immune-checkpoint agonist molecules or 
direct stimulators of immune-system activity.
In this exciting scenario, characterized by the rapid devel-
opment of innovative drugs and the advent of new combina-
tions, personalizing ICIs-based approaches is emerging as the 
main objective of the third phase of the “immune-revolution”, 
in order to identify reliable biomarkers allowing to select the 
right treatment for the right patients at the right moment of his 
cancer history. Since tumor PD-L1 expression is considered as 
a reliable biomarker for single-agent first-line ICI activity, its 
Figure 1 Immune-checkpoint inhibitors combinations in non-oncogene addicted advanced NSCLC.
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predictive role with the new ICI-combinations is currently 
unknown. Several ongoing studies exploring different thera-
peutic approaches, like TIGIT, IDO1, and TGF-β inhibitors, 
are currently recruiting patients with high tumor PD-L1 
expression, suggesting a potential role for such biomarker 
even in the upcoming years. The detection of germline and/or 
somatic mutation in the HRR genes is currently being prospec-
tively investigated as potential predictor of ICI plus PARPi 
combinations benefit, while the HLA expression is the most 
promising biomarker in clinical studies with cancer vaccines. 
A deeper understanding of tumor biology has revealed that 
lung cancer is the result of complex dynamic networks invol-
ving tumor cells’ signaling pathways and tumor microenviron-
ment, suggesting that only an integrated evaluation of both 
cancer genomics and immunomodulating processes will likely 
provide us the most reliable biomarkers to effectively perso-
nalize ICI-based combination approaches. Interestingly, liquid 
biopsy is recently emerging as an additional potential source of 
reliable information, for the real-time monitoring of both 
patients’ disease and immune system status, as well as to 
guide early treatment decisions under ICI therapy. In detail 
Nabet et al provided recent evidence about the DIREct-On 
circulating score, including high pre-treatment blood TMB, 
low peripheral CD8 T-cells count and ctDNA decrease after 
a single ICI infusion, as a potential non-invasive predictor of 
ICI combinations benefit to be validated in the context of 
upcoming clinical trials.110 We are now at the beginning 
of a new period of bottom-up research activity, including 
both pharma-designed clinical trials and spontaneous aca-
demic projects, from which a higher level of biomarker knowl-
edge as well as personalized treatment practices is going to 
progressively emerge.
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